Background
==========

Despite great advances in the development of antibiotics, the most common cause of community-acquired pneumonia, *Streptococcus pneumoniae*, is still a globally important pathogen, especially in children and the elderly \[[@B1]\]. This Gram-positive diplococcus is a leading cause not only of pneumonia, but also otitis media, bacteremia, and meningitis \[[@B2],[@B3]\]. In children, *S. pneumoniae*is estimated to cause more than one-third of the 2 million deaths due to acute respiratory infections \[[@B4],[@B5]\]. In the elderly, *S. pneumoniae*is the most common cause of fatal community-acquired pneumonia \[[@B6],[@B7]\]. In adults from industrialized countries, pneumococcal pneumonia accounts for at least 30% of all cases of community-acquired pneumonia admitted to hospital, with a fatality rate of 11% to 44% \[[@B4]\]. In addition, co-infection of influenza patients with *S. pneumoniae*is known to exacerbate their clinical outcome \[[@B4]\]: for example, 50% or more of the flu-associated mortality in the 1918-1919 Spanish Flu epidemic is believed to have resulted from pneumococcal superinfections \[[@B8],[@B9]\], and *S. pneumoniae*co-infection has been specifically correlated with the severity of the recent H1N1 pandemic influenza \[[@B10]\]. The rate of antibiotic resistance in *S. pneumoniae*has escalated dramatically since penicillin-resistant strains were first detected in the 1970s \[[@B11]-[@B15]\]. About 40% of pneumococcal isolates displayed multidrug-resistant phenotypes (resistance to three or more antibiotics) across 38 countries in 2004 \[[@B16],[@B17]\]. To meet the challenge of increasing pneumococcal drug resistance it will be important to isolate new therapeutic compounds effective against *S. pneumoniae*through the identification of new target enzymes and the development of effective inhibitors to these targets.

The bacterial enzyme alanine racemase (Alr; E.C. 5.1.1.1) uses a covalently-bound pyridoxal 5\"-phosphate (PLP) cofactor to catalyze the racemization of L-alanine and D-alanine, the latter being an essential component of the peptidoglycan layer in bacterial cell walls \[[@B18]\]. Microbiological evidence has consistently shown this enzyme to be essential in bacteria \[[@B19]\]. One apparent exception was found for the *Mycobacterium smegmatis*enzyme, which was able tolerate an insertion in its alanine racemase gene \[[@B20]\]. But this exception was disproved with the report of an alanine racemase deletion mutant in *M. smegmatis*that did not grow without D-alanine supplementation \[[@B19]\]. *S. pneumoniae*, unlike *Escherichia coli*or *Pseudomonas aeruginosa*, contains only one gene that codes for alanine racemase \[[@B21]\]. The lack of alanine racemase function in eukaryotes \[[@B22]\] makes this enzyme an attractive target for antimicrobial drug development. Structural studies are crucial to structure-based drug design \[[@B23]-[@B25]\], and solving the crystal structure of alanine racemase from *S. pneumoniae*(Alr~SP~) is a crucial step towards designing inhibitors of this enzyme.

To date, crystal structures of alanine racemase enzymes from seven different bacteria have been published: *Geobacillus stearothermophilus*(Alr~GS~) \[[@B26]-[@B31]\], *P. aeruginosa*(DadX~PA~) \[[@B32]\], *Streptomyces lavendulae*(Alr~SL~) \[[@B33]\], *Mycobacterium tuberculosis*(Alr~MT~) \[[@B34]\], *Bacillus anthracis*(Alr~BA~) \[[@B35],[@B36]\], *E. coli*(Alr~EC~) \[[@B37]\], and *Enterococcus faecalis*(Alr~EF~) \[[@B38]\]. Structures of this enzyme from a further six microorganisms have been deposited in the PDB: *Bartonella henselae*(PDB ID [3KW3](3KW3)), *Oenococcus oeni*([3HUR](3HUR) and [3CO8](3CO8)), *Pseudomonas fluorescens*([2ODO](2ODO)), *Actinobacillus succinogenes*([3C3K](3C3K)), *Corynebacterium glutamicum*([2DY3](2DY3)), and *Staphylococcus aureus*([3OO2](3OO2)). In all of these structures, Alr is a homodimeric enzyme formed by a head-to-tail association of two monomers. Each monomer is composed of an N-terminal α/β barrel and an extended β-strand domain at the C-terminus. The active site in each monomer is located in the centre of the α/β barrel and contains a pyridoxal phosphate (PLP) co-factor covalently connected to a lysine residue by an internal aldimine bond. The catalytic mechanism is thought to involve two bases, the same lysine, and a tyrosine contributed by the opposite monomer \[[@B30],[@B39],[@B40]\]. The entryway to the active site and the PLP binding site consists of residues from loops in the α/β barrel domain of one monomer and residues from the C-terminal domain of the other monomer, and is roughly conical, with its base oriented toward the outside of the enzyme \[[@B34]\]. Structures of alanine racemase in complex with substrate analogs \[[@B27],[@B28],[@B30]-[@B32]\] and site-directed mutagenesis of the enzyme \[[@B31],[@B40],[@B41]\] have elucidated the reaction mechanism of the enzyme and verified the key roles of active site residues. Structures of alanine racemase complexed with alanine phosphonate and D-cycloserine (DCS) show that these inhibitors covalently bind to the PLP cofactor, which explains their ability to inhibit eukaryotic PLP-containing enzymes in a non-specific manner \[[@B27],[@B30],[@B37],[@B38]\].

Determining the structure of alanine racemase from a range of bacterial species is an important step towards its full characterization in anticipation of inhibitor design. Here, we report the structure of Alr~SP~, and compare it with other published alanine racemase structures. This crystal structure will contribute useful information towards our structure-based drug design research aimed at the identification and development of alanine racemase inhibitors.

Results and discussion
======================

Structure determination and refinement
--------------------------------------

Crystals of Alr~SP~suitable for X-ray diffraction were grown as described previously \[[@B21]\]. Crystals diffracted to a resolution of 2.0 Å and belong to the space group P3~1~21 with the unit cell parameters a = b = 119.97 Å, c = 118.10 Å, α = β = 90° and γ = 120°. The structure of Alr~SP~was solved by molecular replacement using CNS \[[@B42]\] and Alr~GS~(PDB ID [1SFT](1SFT)) \[[@B29]\] without the PLP cofactor as a search model. Refinement was carried out initially with CNS, then completed with TLS refinement \[[@B43]\] in Refmac5 \[[@B44]\]. After structure solution and refinement, the final model of Alr~SP~, validated using PROCHECK \[[@B45]\] has 92.7% of residues in the most favored regions of the Ramachandran plot, 6.9% of residues in the additionally allowed regions and 0.3% of residues in the generously allowed regions. The structure has root-mean-square (r.m.s.) deviations from ideality for bond lengths of 0.015 Å and for angles of 1.45°. Further data collection and refinement statistics are presented in Table [1](#T1){ref-type="table"}.

###### 

Data collection and structure refinement statistics

  Data collection                                     
  --------------------------------------------------- -------------------------------------------
   Unit cell parameters                                a = 119.97 Å, b = 119.97 Å, c = 118.10 Å
                                                       α = 90°, β = 90°, γ = 120°
   Space group                                         P3~1~21
   λ (Å)                                               1.5418
   Mosaicity                                           0.48
   Observations                                        475265
   Unique reflections                                  66748
   R-merge^*a*^(%)                                     8.3 (68.2)
   Completeness (%)                                    99.6 (95.4)
   \<I/σ\>                                             21.3 (1.7)
                                                      
  Refinement statistics                               
                                                      
   Resolution (Å)                                      23.03 - 2.00 (2.05 - 2.00)
   Reflections                                         63336 (4412)
   Total atoms                                         6161
   R-factor^b^(%)                                      16.8 (32.2)
   R~free~(%)                                          20.0 (35.5)
   Average B-factors (Å^2^)                           
    Wilson B-factor                                    33.2
    All atoms                                          42.7
    Main chain atoms                                   41.8
    Side chain atoms and waters                        43.6
    Waters                                             44.5
   R.m.s. deviations                                  
    Bond lengths (Å)                                   0.015
    Bond angles (deg)                                  1.45
   No. of residues                                     734, 100%
   No. of protein atoms                                5615
   No. of PLP atoms                                    30
   No. of benzoic acid atoms No. of water molecules    9 507
                                                      
  Residues in the Ramachandran plot                   
   Most favored regions                                588, 92.7%
   Additionally allowed regions                        44, 6.9%
   Generously allowed regions                          2, 0.3%
   Disallowed regions                                  0, 0%
                                                      

^*a*^R-merge = Σ\|*I*~obs~-*I*~avg~\|/Σ\|*I*~avg~\|

^b^R-factor = Σ\|*F*~obs~-*F*~calc~\|/Σ\|*F*~obs~\|

Values in parenthesis are for the highest resolution shell.

Overall structure of Alr~SP~
----------------------------

Alr~SP~forms a homodimer in which the two monomers form a head-to-tail association, typical of that seen in other alanine racemases. Each monomer has an eight-stranded α/β barrel domain (residues 1-238) and an extended β-strand domain (residues 239-367) (Figure [1A](#F1){ref-type="fig"}). The α/β barrel of one monomer is in contact with the β-strand domain of the other monomer (Figure [1B](#F1){ref-type="fig"}). Although the two monomers have very similar folds, they are crystallographically distinct in this crystal form (Table [1](#T1){ref-type="table"}), and noncrystallographic symmetry was not used in refinement. The r.m.s. difference between the Cα atoms of the two monomers after superposition is 0.38 Å, and the average B-factors of monomers A and B are 38.4 and 46.9 Å^2^, respectively. As with other alanine racemases, the Alr~SP~homodimer contains two active sites, each composed of residues from the α/β barrel of one monomer and residues from the β-strand domain of the other. The pyridoxal phosphate (PLP) cofactor is connected to Lys40 through an internal aldimine bond and resides inside the α/β barrel domain.

![**Structure of alanine racemase from *S. pneumoniae***. (A) Ribbon diagram of the alanine racemase monomer with β-sheets colored green and α-helices colored gold. (B) Ribbon diagram of the alanine racemase dimer where one monomer is colored blue and the opposite monomer red. The N\'-pyridoxyl-lysine-5\'-monophosphate or LLP residue (PLP cofactor covalently bound to lysine; black or grey spheres) resides in the α/β barrel domain of the active site. The active site is composed of residues from the α/β barrel domain of one monomer and residues from the β-strand domain of the other monomer.](1471-2180-11-116-1){#F1}

As an incidental finding, the Alr~SP~structure contained additional electron density within the A monomer, at the end of helix 1 in the N-terminal α/β barrel domain. This planar density resembled a carboxylated aromatic ring, therefore a benzoic acid molecule, which fitted and refined well, was modeled into this region, even though the compound was not added to purification or crystallization conditions (topology and parameters obtained from the Hetero-compound Information Centre-Uppsala, HIC-UP \[[@B46]\]). It is situated some distance away from both the active site entryway and the dimer interface.

Structural and biochemical comparison with closely related alanine racemases
----------------------------------------------------------------------------

As noted in our previous publication \[[@B21]\], Alr~SP~displays a high level of sequence similarity with other alanine racemases. The structure-based sequence alignment in Figure [2](#F2){ref-type="fig"} demonstrates this similarity with alanine racemases from other Gram-positive bacteria: Alr~EF~(which has 52% sequence identity with Alr~SP~), Alr~GS~(46% identity), Alr~BA~(38% identity), and Alr~SL~(36% identity). Regions absolutely conserved across all of these enzymes include the characteristic PLP binding site motif near the N-terminus (AVVKANAYGHG), the two catalytic amino acid residues of the active center (Lys40, Tyr263\'; throughout this paper, primed numbers denote residues from the second monomer) and the eight residues making up the entryway to the active site (inner layer: Tyr263\', Tyr352, Tyr282\', and Ala169; middle layer: Arg307\', Ile350, Arg288\', and Asp170).

![**Structure-based sequence alignment of the five solved alanine racemase structures from Gram-positive bacteria**. Structures are from *S. pneumoniae, G. stearothermophilus*\[[@B29]\], *E. faecalis*\[[@B38]\], *B. anthracis*\[[@B36]\] and *S. lavendulae*\[[@B33]\]. The black box encloses the conserved PLP binding site, the asterisks (\*) mark the PLP-bound Lys residue and the catalytic Tyr residue, the diamond (♦) marks the location of the carbamylated Lys residue, and the residues constituting the entryway to the active site are marked with either **I**(inner layer) or **M**(middle layer). Residues that form intermonomer interfaces are highlighted in light green. The purple shading is proportional to the degree of sequence identity across the alignment.](1471-2180-11-116-2){#F2}

Superposition of the Cα atoms of monomer A from Alr~SP~with equivalent alanine racemase domains from other Gram-positive bacteria confirms the overall topological similarity between these structures (Figure [3A](#F3){ref-type="fig"}). There are minor conformational differences between these alanine racemases at the N- and C-termini and some loops in the α/β-barrel domain. Alr~SP~is similar in length to Alr~SL~and Alr~EF~; whereas Alr~GS~and Alr~BA~have 15 to 19 extra residues at the C-terminus that form an extra β-strand and helix/turn which contact the N-termini and the closest two helices of the α/β-barrel of each structure, and do not form part of the active site. The significance of these extra residues or lack thereof is unknown; future mutagenesis or domain-swap experiments may help to uncover their function.

![**Superposition of alanine racemase monomers from Gram-positive bacteria**. (A) Cα atom traces of alanine racemases from *G. stearothermophilus*(yellow) \[[@B29]\], *E. faecalis*(green) \[[@B38]\], *B. anthracis*(blue) \[[@B36]\], *S. lavendulae*(red) \[[@B33]\], and *S. pneumoniae*(pink). The superposed N-terminal α/β barrel domains are oriented on the bottom of the picture and the C-terminal β-strand domains on the top. Spheres represent the three structurally equivalent residues used to measure the hinge angle in each structure. The double-headed arrow indicates the variation between hinge angles. The PLP-bound Lys residue from Alr~SP~is shown in black. (B) Superposed ribbon representations of the N-terminal domains from *E. faecalis*(green) \[[@B38]\] and *S. pneumoniae*(pink), with the most divergent regions colored orange.](1471-2180-11-116-3){#F3}

Within each alanine racemase, the C- and N-terminal domains of each monomer are structurally distinct, and the hinge angle varies between the different enzymes \[[@B32],[@B36]\], thereby preventing the optimal superposition of whole monomers. Overlaying the Cα atoms of Alr~SP~and alanine racemase structures from other Gram-positive bacteria results in average r.m.s. differences of 1.16-1.57 Å (Table [2](#T2){ref-type="table"}), but when the N-terminal and C-terminal domains from Alr~SP~are superimposed separately, the C-terminal domain is shown to be more conserved (average r.m.s. differences of 0.49-1.24 Å), than the N-terminal domain (r.m.s. of 1.30-1.92 Å). Domain boundaries and residues used in these superpositions are listed in Table [3](#T3){ref-type="table"}. The subset of residues found in the active site of Alr~SP~superpose very well with the equivalent residues of the other structures (r.m.s. of 0.36-0.67 Å). C-termini and active site residues superpose particularly well between Alr~SP~and Alr~GS~, and also between Alr~BA~and Alr~EF~. This structural similarity explains why Alr~GS~was such a successful molecular replacement model. Variability in the N-terminal domain is further illustrated by superposition of the N-terminal domains of Alr~SP~and its closest available homolog, Alr~EF~, which reveals significant deviations in Cα positions (≥1.8 Å) for five regions: residues 27-29, residues 53-58, residues 109-122, residues 150-156, and residues 192-196 (Figure [3B](#F3){ref-type="fig"}). The sequence in these regions is not highly conserved and they lie far from the active site. Superposition of the C-terminal domains from these structures shows no region with Cα differences greater than 1.7 Å. Overall, alanine racemase structures seem to tolerate significant alterations in the backbone of the α/β-barrel and β-domain and still retain almost identical active site residue locations.

###### 

Average r.m.s. differences (Å) between the Cα atoms of Alr~SP~and alanine racemase structures from other Gram-positive bacteria

            PDB ID         Whole monomer   N-terminus   C-terminus   Active site
  --------- -------------- --------------- ------------ ------------ -------------
  Alr~GS~   [1SFT](1SFT)   1.23 (46%)      1.30 (41%)   0.57 (56%)   0.36 (66%)
                                                                     
  Alr~SL~   [1VFH](1VFH)   1.57 (38%)      1.92 (34%)   1.24 (41%)   0.67 (46%)
                                                                     
  Alr~BA~   [3HA1](3HA1)   1.29 (45%)      1.59 (41%)   0.49 (53%)   0.38 (65%)
                                                                     
  Alr~EF~   [3E5P](3E5P)   1.16 (53%)      1.48 (52%)   0.54 (56%)   0.46 (71%)

Numbers in parenthesis denote sequence identity with AlrSP, (%sequence identity = Nidentity/Naligned).

###### 

Residues used in r.m.s. calculations

                                **Alr**~**EF**~   **Alr**~**SP**~   **Alr**~**GS**~   **Alr**~**BA**~   **Alr**~**SL**~
  ----------------- ----------- ----------------- ----------------- ----------------- ----------------- -----------------
  **N-terminus**    monomer A   2-243             1-239             2-241             4-245             3-246
                                                                                                        
  **C-terminus**    monomer A   244-371           240-367           242-388           246-389           247-378
                                                                                                        
  **Active site**   monomer A   38-44             38-44             37-43             39-45             36-42
                                                                                                        
                                62-66             61-65             61-65             63-67             60-64
                                                                                                        
                                83-87             82-86             82-86             84-88             81-85
                                                                                                        
                                100-104           101-105           101-105           103-107           100-104
                                                                                                        
                                128-141           125-138           125-138           127-140           125-138
                                                                                                        
                                164-172           160-168           161-169           163-171           163-171
                                                                                                        
                                201-208           197-204           198-205           203-210           203-210
                                                                                                        
                                219-226           215-222           216-223           221-228           221-228
                                                                                                        
                                353-360           349-356           351-358           356-363           358-365
                                                                                                        
                    monomer B   265-268           261-264           263-266           268-271           268-271
                                                                                                        
                                311-316           307-312           309-314           314-319           315-320

The kinetic properties for Alr~SP~\[[@B21]\] are within the range of those previously observed for other bacterial alanine racemases (Table [4](#T4){ref-type="table"}). The K~M~for L-alanine is 1.9 mM and V~max~for the racemization of L- to D-alanine is 84.8 U/mg, where one unit is defined as the amount of enzyme that catalyzes racemization of 1 μmol of substrate per minute. In the other direction, the K~M~for D-alanine is 2.1 mM and V~max~for the racemization of L- to D-alanine is 87.0 U/mg. However, the V~max~for the *S. pneumoniae*enzyme is more than one order of magnitude lower than that reported for the *G. stearothermophilus*and *E. faecalis*enzymes, even though the active site of Alr~SP~has high sequence and structural similarities with these alanine racemases. Differences of up to three orders of magnitude have been reported in this family despite very similar active sites.

###### 

Kinetic parameters for the racemization of L- to D- and D- to L-alanine by alanine racemases from Gram-positive bacteria

                              D to L direction         L to D direction                                                                                                                         
  --------------------------- ------------------------ ----------------------------------- --------------------------------------- ------------------------ ----------------------------------- ---------------------------------------
  **Enzyme \[ref\]**          **K**~***m***~**(mM)**   **V**~***max***~**(U/mg)**^**a**^   **k**~***cat***~**(min**^**-1**^**)**   **K**~***m***~**(mM)**   **V**~***max***~**(U/mg)**^**a**^   **k**~***cat***~**(min**^**-1**^**)**
                                                                                                                                                                                                
  **Alr**~**SP**~\[[@B21]\]   2.1^b^                   87.0^b^                             NR                                      1.9^b^                   84.8^b^                             NR
                                                                                                                                                                                                
  **Alr**~**GS**~\[[@B76]\]   2.7^c^                   1400^c^                             NR                                      4.3^c^                   2550^c^                             NR
                                                                                                                                                                                                
  **Alr**~**SL**~\[[@B77]\]   0.4^c^                   NR                                  3800^c^                                 0.4^c^                   NR                                  3300^c^
                                                                                                                                                                                                
  **Alr**~**BA**~\[[@B36]\]   2.8^b^                   101^b^                              NR                                      NR                       NR                                  NR
                                                                                                                                                                                                
  **Alr**~**EF**~\[[@B78]\]   2.2^c^                   1210^c^                             \~2340^c^                               7.8^c^                   3570^c^                             \~2340^c^
                                                                                                                                                                                                
                                                                                                                                                                                                

^a^One unit is defined as the amount of enzyme that catalyzes racemization of 1 μmol of substrate per minute.

^b^At 23°C. ^c^At 37°C. NR: not reported.

Hinge angle
-----------

The hinge angle of the A monomer of Alr~SP~, formed by the Cα atoms of residues 99, 38 and 270 in the N-terminal α/β barrel domain and the C-terminal β-strand domain, is 132.3°. This is well within the range of hinge angles found between corresponding residues in the other Gram-positive alanine racemase structures (127.6° for Alr~BA~, 129.4° for Alr~GS~, 131.6° for Alr~EF~, and 138.2° for Alr~SL~). The difference in the degree of tilt between the C-terminal domains for the five structures can be seen in Figure [3A](#F3){ref-type="fig"}. Hydrogen bonding between the C- and N-terminal tails of opposite monomers was proposed by LeMagueres *et al.*to account for the distinct domain orientations of Alr~MT~and DadX~PA~\[[@B34]\]. Alanine racemase structures with extra residues at the N- and C-terminal tails, such as Alr~GS~and Alr~BA~, often form these hydrogen bonds, which are associated with smaller hinge angles (127.6° for Alr~BA~, 129.4° for Alr~GS~)\[[@B36]\].

Although the hinge angle clearly varies from species to species for this enzyme, the active sites superpose very well. Further, there is no correlation between hinge angle and Vmax (data not shown). On the other hand, there is some correlation between alanine racemase activity and bacterial doubling time. For example, the enzyme from the slow growing *M. tuberculosis*is very slow compared to the same enzyme from the rapid growing *M. smegmatis*species. It has previously been noted that only the dimeric form of the enzyme is active \[[@B47]\] and that many of the alanine racemase enzymes with the strongest monomer-dimer association have been found to be the most active \[[@B48]\]. A recent report has appeared looking at how enzyme activity in different alanine racemases relates to self-association affinity and this report confirms this assertion \[[@B49]\].

Active site
-----------

The geometry and identities of the active site residues of Alr~SP~(Figure [4A](#F4){ref-type="fig"}) are very similar to that of other alanine racemases (Figure [4B](#F4){ref-type="fig"}). The main components of the Alr~SP~active site include the PLP cofactor covalently bound to Lys40 (forming an N\'-pyridoxyl-lysine-5\'-monophosphate or LLP residue), the catalytic base residue Tyr263\' which lies at the beginning of helix 11 in the β-strand domain (contributed by the opposite monomer to that providing Lys40), and a hydrogen-bonded network of residues (Figure [5](#F5){ref-type="fig"}). Based on the reaction mechanism of alanine racemases proposed elsewhere \[[@B29]-[@B31],[@B50]\], Alr~SP~operates by a two-base mechanism where the α-hydrogen of either D-alanine or L-alanine is abstracted and added by a different catalytic residue. Therefore, in the D- to L- direction, the reaction occurs with D-alanine binding to produce an external aldmine between PLP and D-alanine. Lys40 then abstracts the α-hydrogen to produce a carbanonic quinonoid intermediate. Next, Tyr263\' adds a proton to the Cα of the intermediate from the opposite side to produce an external aldimine between PLP and what is now L-alanine. Subsequent transaldimination liberates L-alanine and regenerates the LLP form of the enzyme.

![**Active site of alanine racemase from *S. pneumoniae***. (A) Electron density 2F~o~-F~c~map of the active site contoured at 1.5σ, excluding solvent. Residues from the first monomer are colored pink, residues from the second monomer are blue and are denoted with primed numbers. The PLP-bound Lys residue (LLP) is grey. (B) Superposition of the active site residues from Gram-positive alanine racemase structures with Alr~SP~; only *S. pneumoniae*residues are labeled. Residues pictured are from *G. stearothermophilus*(yellow) \[[@B29]\], *E. faecalis*(green) \[[@B38]\], *B. anthracis*(blue) \[[@B36]\], *S. lavendulae*(red) \[[@B33]\], and *S. pneumoniae*(pink). The chloride ion from the *B. anthracis*structure is depicted as a blue sphere. (C) Unmodeled electron density (green) found in the active site. 2F~o~-F~c~(light blue) and F~o~-F~c~(green and red) maps are contoured at 1.5 and 3.0 σ, respectively. Residues are colored and labeled as described for Figure 4A.](1471-2180-11-116-4){#F4}

![**Schematic diagram of polar interactions around PLP in the active site of alanine racemase from *S. pneumoniae***. For clarity, interactions with water molecules have not been included. Primed numbers denote residues from the second monomer. This figure was drawn after LeMagueres *et al.*\[[@B32]\].](1471-2180-11-116-5){#F5}

In the LLP moiety, the C4\" atom of the PLP cofactor is linked to the NZ of Lys40 by a double bond in the *trans*- configuration, forming an internal aldimine as in other alanine racemase structures \[[@B29],[@B31]-[@B33]\]. The PLP cofactor is further stabilized by hydrogen bonds with the side chains of six residues (Tyr44, Arg136, His165, Ser203, Arg218 and Tyr352) and main chains of three residues (Ser203, Gly220, Asp221; Figure [4A](#F4){ref-type="fig"}). The hydrogen-bonded network also includes residues His199 and Tyr263\", and was first described in Alr~GS~\[[@B29]\]. All of these residues are strictly conserved across the Gram-positive structures, except for Asp221, which is replaced by an Ile in Alr~BA~and Alr~GS~, a Val in Alr~EF~, and a Leu in Alr~SL~\[[@B29],[@B33]\].

We observed electron density consistent with a carbamylated lysine at the NZ terminus of Lys129, as seen in most other alanine racemase structures. Lys129 refined well as a carbamylated residue in this structure and is hydrogen bonded to the neighboring arginine residue. Shaw *et al.*\[[@B29]\] noted that this lysine residue is highly conserved, and later studies suggested that it helps to position the nearby arginine residue (Arg136 in Alr~SP~) which interacts with the substrate\'s carboxylate group through hydrogen-bonding \[[@B28],[@B32]\]. Arg136 is further positioned in Alr~SP~by a hydrogen bond to Ser309. Sequences of alanine racemases that contain a lysine in position 129 almost always have an accompanying serine or cysteine residue in the equivalent of position 309 \[[@B36]\]. Recently, the Alr~BA~structure was found to contain an aspargine residue bound to a chloride ion at the equivalent position of Lys129, which appears to play the same role as the carbamylated Lys of positioning the active site arginine \[[@B36]\]. An alignment of alanine racemase sequences by Couñago *et al.*revealed that the presence of an aspargine residue can occur at the equivalent position of Lys129 in Alr~SP~and is likely to be indicative of an internal chloride within the active site in the place of a carbamylated lysine. Notably this change from Lys to Ser appears to always be accompanied by a threonine at the equivalent position of Ser309, even though the threonine does not directly interact with the chloride ion.

The environments on either side of the pyridine ring of PLP are quite different, as reported previously for Alr~GS~\[[@B29],[@B33]\]. The side of the PLP that faces the dimer interface is polar in character, with many hydrophilic amino acid residues (including carbamylated Lys129, Arg136, His165 and Arg218), several water molecules and the hydrogen-bond network. The nonpolar side of PLP, in contact with the α/β barrel, contains several hydrophobic residues (Val38, Leu83, Leu85 and Phe163), no charged residues and no water molecules.

As observed in several other alanine racemase structures \[[@B29],[@B32],[@B34],[@B36]\], we identified extra density in the active site of Alr~SP~adjacent to the PLP cofactor (Figure [4C](#F4){ref-type="fig"}). The position of this density corresponds to that of the acetate modeled in Alr~GS~. In other structures, this location has been reported to contain propionate, alanine phosphonate, and a putative substrate molecule in DadX~PA~\[[@B28]-[@B30],[@B38]\]. Water molecules in the same location are found in the Alr~MT~and Alr~SL~structures. After unsuccessfully attempting to model a variety of small molecules into the extra density, including acetate, we left this region of the model empty.

Active site entryway
--------------------

The entryway to the active site in Alr~SP~comprises the α/β barrel domain of one monomer and residues from the C-terminal domain of the other monomer, and is about 13 Å from the active site C4\" atom of PLP. The entryway has a funnel-like shape, with its widest end towards the outside of the enzyme, narrowing as it approaches the PLP. The highly conserved residues comprising the entryway are distributed in layers beginning at the PLP site (Figures [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}): charged near the entrance, and mainly hydrophobic near the active site \[[@B33],[@B34]\]. Mutagenesis has shown that these hydrophobic residues have an important role in controlling the substrate specificity of alanine racemase \[[@B51]\]. In Alr~SP~, the inner layer is made up of residues Tyr263\', Tyr352, Tyr282\', and Ala169. Residues Arg307\', Ile350, Arg288\', and Asp170 make up the middle layer. The residues composing the middle and the inner layers are strictly conserved between Alr~SP~, Alr~EF~, Alr~BA~, Alr~GS~, and Alr~SL~. An outer layer exists comprised of Thr345, Glu171, Val232 and Gly264\', but these residues, which are able to interact with solvent directly, are not well conserved.

![**Molecular surface representations of the entryway to the active site of alanine racemase from *S. pneumoniae***. (A) The surface of three layers of entryway residues: residues comprising the inner layer are pink (here, the constricting Tyr352 and Tyr263\' residues can be seen), the middle layer residues are orange, and the outer layer residues are blue. The PLP cofactor is colored green. Primed numbers denote residues from the second monomer. (B) Surface of the entryway colored by electrostatic potential (same view as in A).](1471-2180-11-116-6){#F6}

The Alr~SP~active site entryway includes the conserved pair of acidic residues Asp170 and Glu171. The equivalent residues in *E. coli*, Asp164 and Glu165, have been posited to play a role in substrate orientation \[[@B37]\]. Although the active sites of alanine racemases in general are moderate in size, it is difficult for inhibitors to access because of a constriction in the entryway corridor \[[@B34]\]. The smallest constriction in the entryway corridor of Alr~SP~is between Tyr263\' and Tyr352 of the inner layer (Figure [6A](#F6){ref-type="fig"}), which provide an opening width of only about 2.6Å for an active site inhibitor to pass through (the distance between the closest atoms of these two side chains with the van der Waals radius for each atom subtracted). As a result, the substrate entryway itself has been proposed as an alternative target for inhibitor development \[[@B32],[@B34]\]. Wang *et al.*\[[@B52]\] have proposed this idea previously for another enzyme, histone deacetylase-like protein.

Dimer interface
---------------

Dimerization is essential for the catalytic activity of alanine racemase \[[@B47]\]. Both monomers contribute to the overall composition of the active site, the alanine entryway, and the binding pocket. Within the Alr~SP~dimer interface there are 33 hydrogen bonds and 10 salt bridges (Table [5](#T5){ref-type="table"}). There are no disulfide or covalent bonds across the interface. 91 residues from each monomer are involved in intermonomer interactions. The buried surface areas of the A and B monomers are 3035 and 3020 Å^2^, respectively; both values are 19% of the total surface area of each monomer. The interface surface area is similar to that seen in the closely related Alr~EF~and Alr~GS~(Table [5](#T5){ref-type="table"}). 30% of the interface residues in Alr~SP~are polar, 47% are non-polar, and 22% are charged.

###### 

Intermonomer interactions for alanine racemases from Gram-positive bacteria calculated using PISA \[[@B69]\] and PROTORP \[[@B70]\]

            Buried surface area (Å^2^)   H-bonds   Salt link   \# residues   \% interface residues                  
  --------- ---------------------------- --------- ----------- ------------- ----------------------- ---- ---- ---- ----
  Alr~SP~   3035                         3020      33          10            91                      91   30   47   22
                                                                                                                    
  Alr~GS~   3058                         3109      43          17            89                      88   27   43   30
                                                                                                                    
  Alr~SL~   2800                         2799      26          6             87                      87   39   43   18
                                                                                                                    
  Alr~BA~   3529                         3529      45          10            93                      95   28   44   27
                                                                                                                    
  Alr~EF~   2936                         2936      38          12            86                      86   32   41   28

Disruption of the dimer interface could be used to inhibit alanine racemase activity, and has been successfully used on drug targets in HIV and HCV \[[@B53]-[@B55]\], and on caspases \[[@B56]\]. Inspection of the residues that participate in the dimer interface of Alr~SP~on a structure-based sequence alignment (Figure [2](#F2){ref-type="fig"}) makes it apparent that that many of these residues are highly conserved, and also participate in substrate guidance (such as middle and inner entryway residues Tyr282\', Tyr352, Arg307\', Ile350, Arg288\', Asp170) or catalysis (e.g. Lys40, Tyr263\').

Pentagonal water molecules in the active site
---------------------------------------------

A cluster of hydrogen-bonded water molecules forms an ordered pentagonal ring and some adjacent partial rings in the active site entryways of both monomers of Alr~SP~(Figure [7](#F7){ref-type="fig"}). The pentagonal ring waters are located adjacent to the substrate binding site and between residues Tyr263\" and Tyr282\". They are positioned at the interface of monomer A and B and appear to be involved in the dimer interface, making direct or indirect hydrogen bonds with interface residues (Asp170, Tyr263\', Tyr282\', Tyr288\', Arg307\', Tyr352). The distance between the water oxygen atoms that form each side of the pentagon is about 2.7 Å. The pentagonal ring is hydrogen-bonded directly to the protein at five atoms (Tyr282\' OH, Arg307\' NH1, and Arg288\' NH2 and NE from the entryway inner and middle layers, and Val308\' O) and makes hydrogen bonds with other waters both deeper in the active site and at the outer region of the entryway.

![**Pentagonal ring waters near the substrate binding site in alanine racemase from *S. pneumoniae***. The electron density 2F~o~-F~c~map is contoured at 0.8σ. Residues are shown as sticks, red spheres represent water molecules, and dashed yellow lines represent hydrogen bonds. Residues from the first monomer are colored pink, residues from the second monomer are blue and are denoted with primed numbers. The PLP-bound Lys residue (LLP) is grey. For simplicity, only some of the residues are shown.](1471-2180-11-116-7){#F7}

The hydrogen bond network we have identified could be facilitating substrate movement or proton transfer into the active site. Analysis of conserved water sites in Alr~GS~has been reported previously and the authors postulated that these sites could be involved in proton transfer or solvent shift into the active site \[[@B57]\]. In the high resolution structure of the protein crambin, Teeter reported pentagonal rings of water molecules which were felt to have a role in stabilizing protein structure or in catalysis \[[@B58]\]. Pentagonal ring waters have not yet been reported for other alanine racemases, but depending on which monomer is observed, the Alr~BA~and Alr~GS~structures have 3 to 4 of the 5 pentagonal waters present in Alr~SP~, the Alr~SL~structure has 2 of the 5 pentagonal waters, and the Alr~EF~structure does not have any pentagonal ring waters, although this could be due to limits in structural resolution.

Alanine racemase as a target for drug design
--------------------------------------------

In this section we review some of the challenges encountered in developing inhibitors for alanine racemases as a family and we explain the contribution of the *S. pneumoniae*structure to this process. Finally we offer our assessment of the most useful approaches to alanine racemase inhibitor development.

Challenges involved in designing inhibitors for alanine racemase are easy to identify. To begin with, there have been few reports to date of alanine racemase inhibitors with any true specificity. Incorporating features of the active site in drug design has been challenging because the structure of the active site is thought to have limited accessibility. Further, several inhibitors have been found to cross react with human enzymes that contain PLP. Even so, our analysis of alanine racemase structures has allowed us to identify key features that could be incorporated into the inhibitor development process. Since these key features are also present in the *S. pneumoniae*enzyme structure, it confirms that these features are not artifacts or incidental findings but conserved features that can be targeted in the development of a class of inhibitors specific to bacterial alanine racemases. Therefore the structure of the *S. pneumoniae*enzyme is valuable to racemase drug design efforts.

In addition, one new feature relevant to the traditional drug design approach of blocking the active site that we report here for Alr~SP~is the pentagonal water network within the active site. Several of these waters are conserved in other alanine racemase species. That being the case, the conserved waters could be incorporated within an *in silico*pharmacophore as a polar site capable of receiving or donating a hydrogen bond depending on its protonation state. Unfortunately, to date testing of compounds identified from *in silico*screening has not resulted in the identification of strong inhibitors.

The earliest drug development work on alanine racemase was carried out in the absence of a crystal structure and resulted in the development of a cycloserine, a small, covalent inhibitor of alanine racemase and other PLP-containing enzymes \[[@B59]\] that lacks any specific interactions with elements in the active site. More recent *in silico*drug design work carried out using the structure of alanine racemase has defined a pharmacophore situated within the active site near the alanine racemase acetate binding site, a site reported consistently within alanine racemase structures \[[@B60]\]. However, analysis of the narrow entryway to the active site PLP suggests that access to the proposed interior binding pockets of the enzyme is likely to be limited, especially for larger compounds \[[@B32],[@B34]\]. To be an effective drug target it is important the active site be accessible, therefore standard structure-aided inhibitor design approaches are limited for alanine racemase.

Since, as illustrated by the Alr~SP~structure, entryway to the interior binding pocket of alanine racemase is very tight, the drug design problem for alanine racemase resembles a \"ship in a bottle\" (SIAB) dilemma. Once inside the interior pocket, the compounds proposed to bind to the active site would fit well but these compounds may only make it to the interior with difficulty \[[@B32],[@B34],[@B36]\]. This view is of course an oversimplification, as the entryway is likely to \'breathe\' and adjust, and there is a monomer-dimer equilibrium for alanine racemase that would affect the geometry and accessibility of internal active site cavities. However, the restricted access and size of the alanine racemase active site is one reason it has not been targeted by major pharmaceutical companies in the recent past (Bussiere, Dirk; personal communication).

If a drug design project involving an enzyme with a SIAB active site is to be successful, there are four obvious approaches to inhibitor development: high throughput screening (HTS), blocking the opening, interfering with active site assembly, or developing drugs that enter in one shape and adopt a new conformation after binding, thus trapping them in the active site.

HTS would bypass any of the complexities associated with active site access and would provide a set of compounds that inhibit the enzyme by any and all means, to be deconvoluted later. Given that the active site features we describe for the *S. pneumoniae*enzyme are highly conserved in the bacterial structures reported to date, the alanine racemase inhibitors identified by HTS would likely be broad-spectrum in their action. But a broad spectrum of activity should not be viewed in a negative light, as almost all major classes of antibiotics developed to date are broad spectrum. This includes beta-lactams like penicillin and cephalosporins, fluoroquinolones, tetracyclines, even macrolides. In fact the only specificity among anti-bacterial classes currently in use would be that some target preferentially Gram-positives, Gram-negatives, mycobacteria or anaerobes.

Blocking the opening would involve the design of compounds that interact with residues in the entryway and that extend toward the PLP moiety, but that might not reach the interior binding pocket. In our previous work on the alanine racemase from *P. aeruginosa, M. tuberculosis*and *B. anthracis*, we described a highly conserved and layered entryway to the active site that contains both hydrophobic and polar features. The hydrophobic regions are bound by three tyrosines and an alanine in the inner layer of entryway, while the polar areas include two arginines and one aspartate located in the middle layer. These highly conserved features are present in the *S. pneumoniae*structure and all alanine racemase structures reported to date. An entryway of this type has not been described in human PLP-containing enzymes. For example, human serine racemase, which like alanine racemase reacts with D-cycloserine, belongs to the Fold type II family of PLP-containing enzymes and would be not be expected to cross-react with any specific alanine racemase inhibitors \[[@B61]\]. The alanine racemase topology is termed Fold type III and is unique among PLP-containing enzymes. It seems likely, therefore, that designing inhibitors that interact with conserved motifs found in the entryway could represent a potential source of specificity in the drug design process.

Interfering with active site assembly would, in the case of alanine racemase, require compounds that inhibit dimer formation, none of which have been reported for alanine racemase to date. However, dimer inhibitors have been reported in other systems such as HIV protease \[[@B53]-[@B55]\]. Finally, a compound that could enter the active site of alanine racemase then undergo a conformational switch rendering the enzyme inactive would make an effective inhibitor, but this type of inhibitor has not yet been reported for this class of enzyme.

Conclusions
===========

Alanine racemase is a promising target for antibacterial drugs because it is both essential in bacteria and absent in humans. We report the high-resolution crystal structure of alanine racemase from *S. pneumoniae*. Overall, the structure shares the conserved active site and topology found across all alanine racemases. Known alanine racemase inhibitors such as D-cycloserine, alanine phosphonate, and other substrate analogues are not specific, acting on other PLP-containing enzymes such as transaminases, also found in humans \[[@B59],[@B62]\]. In order to be clinically relevant, new inhibitors of alanine racemase with more specificity need to be developed. This structure is an essential starting point for the design of more specific inhibitors of alanine racemase in *S. pneumoniae*. Our investigations have identified three potential areas in the Alr~SP~structure that could be targeted in a structure-based inhibitor design: the active site, the residues forming the dimer interface, and the active site entryway in particular, since designing a \'plug\' to fit the funnel shape of this feature is intuitively attractive.

Methods
=======

Protein expression, purification and crystallization
----------------------------------------------------

The expression, purification and crystallization of Alr~SP~have been described previously \[[@B21]\]. Briefly, the gene encoding Alr~SP~was cloned into pET17 (Novagen) and the resulting vector transformed into *E. coli*BL21 (DE3) pLysS cells (Novagen). Overexpression of Alr~SP~was induced in a culture of these cells, which were then lysed to extract the protein. The recombinant Alr~SP~was purified using ammonium sulfate precipitation, anion-exchange chromatography, hydrophobic interaction chromatography, and finally, size-exclusion chromatography. Crystals of Alr~SP~were grown at 4°C in 1.2 M Na Citrate, 0.1 M MES, pH 7.2, and 10% glycerol (protein concentration 23 mg/ml, drop size 4 μl + 4 μl) using the sitting drop vapor diffusion method, then flash-frozen in liquid N~2~for data collection. No additional cryoprotectant was required.

Data collection and processing
------------------------------

Diffraction data were collected to 2.0 Å resolution at 100 K using a Rigaku FR-E generator and an HTC detector at 45 kV and 45 mA with Cu Kα radiation at Rigaku MSC (The Woodlands, TX). The crystals belonged to the space group P3~1~21 with the unit cell parameters a = b = 119.97 Å, c = 118.10 Å, α = β = 90° and γ = 120°. The data were processed and merged using the HKL package version 1.96.6 \[[@B63]\]. Data collection and processing statistics are listed in Table [1](#T1){ref-type="table"}.

Structure determination and refinement
--------------------------------------

The structure of Alr~SP~was solved by molecular replacement using CNS version 1.1 \[[@B42]\]. Alr~GS~(PDB ID [1SFT](1SFT)) \[[@B29]\] without the PLP cofactor was used as a search model, and two monomers per asymmetric unit were assumed, as suggested by a Matthews coefficient \[[@B64]\] of 3.0 with a solvent content of 59.0%. Cross-rotation and translation searches were completed and the best solution was used as an initial model for model building. After rigid body refinement in CNS, ARP/wARP version 6.1 \[[@B65]\] was used to trace the initial protein model and build side chains. Further refinement was carried out using simulated annealing and conjugation gradient minimization. When 97% of residues were built, the co-factor PLP and the carbamylated lysine were placed, and positional and B-factor refinements were continued resulting in an R and R~free~of 31.9 and 33.9%, respectively. Water molecules were added using the water-picking script in CNS, and further cycles of positional and B~iso~refinements brought the R and R~free~to 20.7 and 25.7%, respectively. Since previous alanine racemase structures have shown indications of subdomain movement, we tried TLS refinement \[[@B43]\]. We used the TLS motion determination server \[[@B66],[@B67]\] to produce modified PDB files and TLS input files for the structure partitioned into either one, five or twenty TLS groups, then further refined these models in Refmac5 version 5.5.0109 \[[@B44]\]. All models resulted in similar improvements in R and R~free~so we used the simplest option, which treated all protein atoms found in the asymmetric unit as a single rigid body (one TLS group). PLP and Lys40 were replaced with an LLP residue (PLP covalently bound to lysine), and TLS refinement was completed using Refmac5. The final model has an R and R~free~of 16.8 and 20.0%, respectively. Refinement statistics are listed in Table [1](#T1){ref-type="table"}. Structure factors and final atomic coordinates for AlrSP have been deposited in the Protein Databank (PDB ID: [3S46](3S46)). B-factor values and correlation coefficients were calculated using the programs Baverage and Overlapmap from the CCP4 suite \[[@B44]\].

Structural and sequence comparisons
-----------------------------------

The multiple structure-based sequence alignment and structural superpositions of Alr~SP~with closely related structures were performed using the protein structure comparison service (SSM) at the European Bioinformatics Institute (<http://www.ebi.ac.uk/msd-srv/ssm>) \[[@B68]\]. The PDB IDs of the structures used were: [1SFT](1SFT) (Alr~GS~), [1VFH](1VFH) (Alr~SL~), [3HA1](3HA1) (Alr~BA~), and [3E5P](3E5P) (Alr~EF~). Table [3](#T3){ref-type="table"} lists the residues from these structures used in the superpositions. Intermonomer interactions were analysed using the Protein Interfaces, Surfaces and Assemblies service (PISA) at the European Bioinformatics Institute (<http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html>) \[[@B69]\], and the Protein-Protein interface analysis server (PROTORP) Server (<http://www.bioinformatics.sussex.ac.uk/protorp/> index.html) \[[@B70]\].

Figure preparation
==================

Representations of molecules were prepared using the programs PyMOL \[[@B71]\] and BKChem (<http://bkchem.zirael.org/index.html>). The sequence alignment was visualized using Jalview \[[@B72]\]. The electrostatic potential of the Alr~SP~surface was calculated using the Adaptive Poisson-Boltzmann Solver (APBS) \[[@B73]\] through PyMOL. Default configurations were used for calculations. PQR files for use with APBS were generated using the PDB [2PQR](2PQR) Server (<http://kryptonite.nbcr.net/pdb2pqr/>) \[[@B74]\] and the Dundee PRODRG2 Server (<http://davapc1.bioch.dundee.ac.uk/prodrg/>) \[[@B75]\].
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